Center for Cancer Nanotechnology Excellence for Translational Diagnostics (CCNE-TD)

转化诊断癌症纳米技术卓越中心 (CCNE-TD)

基本信息

批准号：
9324940
负责人：
SANJIV S GAMBHIR
金额：
$ 204.91万
依托单位：
STANFORD UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2015
资助国家：
美国
起止时间：
2015-09-04 至 2020-07-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9324940
关键词：
Advanced Malignant Neoplasm Aftercare Animal Model Biological Markers Biopsy Blood Blood Tests Blood specimen CCNE1 gene Cancer Center Cancer Detection Cancer Patient Cells Clinical Clinical Management Clinical Trials Collaborations Communities Deoxyglucose Development Devices Diagnostic Discrimination Disease Early Diagnosis Early treatment Ensure Five-Year Plans Foundations Funding Future Goals Health Transition Image Image Guided Biopsy Imaging technology In Vitro Individual Indolent Institutes Intervention Link Location Lung Neoplasms Malignant Neoplasms Malignant neoplasm of lung Malignant neoplasm of prostate Massachusetts Measures Medical Methods Molecular Biology Techniques Monitor Nanotechnology Neoplasm Circulating Cells Oncologist Patient-Focused Outcomes Patients Phase Physicians Positron-Emission Tomography Process Prostate Recording of previous events Regimen Research Research Proposals Resources Role Running Sampling Sampling Studies Scientist Screening for cancer Serinus Signal Transduction Site Survival Rate Technology Testing Therapeutic Therapeutic Intervention Tracer Translating Tumor Burden Ultrasonography Universities Vesicle Vision anticancer research base biophysical analysis cancer biomarkers cancer diagnosis cancer survival cancer therapy chemotherapy clinical translation cohesion cost cost effective extracellular extracellular vesicles high risk improved in vivo industry partner innovation lung cancer screening lung visualization molecular imaging multidisciplinary nano nanoimaging nanoparticle nanoscience nanosensors next generation novel photoacoustic imaging prognostic programs protein biomarkers public health relevance responders and non-responders response single cell analysis single cell technology surveillance study synergism translational diagnostics tumor tumor heterogeneity tumorigenesis

Advanced Malignant Neoplasm Aftercare Animal Model Biological Markers Biopsy Blood Blood Tests Blood specimen CCNE1 gene Cancer Center Cancer Detection Cancer Patient Cells Clinical Clinical Management Clinical Trials Collaborations Communities Deoxyglucose Development Devices Diagnostic Discrimination Disease Early Diagnosis Early treatment Ensure Five-Year Plans Foundations Funding Future Goals Health Transition Image Image Guided Biopsy Imaging technology In Vitro Individual Indolent Institutes Intervention Link Location Lung Neoplasms Malignant Neoplasms Malignant neoplasm of lung Malignant neoplasm of prostate Massachusetts Measures Medical Methods Molecular Biology Techniques Monitor Nanotechnology Neoplasm Circulating Cells Oncologist Patient-Focused Outcomes Patients Phase Physicians Positron-Emission Tomography Process Prostate Recording of previous events Regimen Research Research Proposals Resources Role Running Sampling Sampling Studies Scientist Screening for cancer Serinus Signal Transduction Site Survival Rate Technology Testing Therapeutic Therapeutic Intervention Tracer Translating Tumor Burden Ultrasonography Universities Vesicle Vision anticancer research base biophysical analysis cancer biomarkers cancer diagnosis cancer survival cancer therapy chemotherapy clinical translation cohesion cost cost effective extracellular extracellular vesicles high risk improved in vivo industry partner innovation lung cancer screening lung visualization molecular imaging multidisciplinary nano nanoimaging nanoparticle nanoscience nanosensors next generation novel photoacoustic imaging prognostic programs protein biomarkers public health relevance responders and non-responders response single cell analysis single cell technology surveillance study synergism translational diagnostics tumor tumor heterogeneity tumorigenesis

展开

项目摘要

DESCRIPTION (provided by applicant): This Center for Cancer Nanotechnology Excellence for Translational Diagnostics (CCNE-TD) brings together scientists and physicians from Stanford University and the Massachusetts Institute of Technology to tackle the grand challenges of cancer early detection, image guided biopsy, monitoring response to therapy and early discrimination of aggressive vs. indolent disease. This research proposal is centered on our vision that in vitro diagnostics used in conjunction with in vivo molecular imaging can markedly impact future cancer patient management. Furthermore, we believe that nanotechnology can significantly advance both in vitro diagnostics through nanosensors, and in vivo diagnostics through nanoparticles for molecular imaging. The two major cancers that we will study are lung and prostate cancer. For lung cancer we will apply our technologies for early detection and to monitor response to therapy. For prostate cancer we will use our technologies to improve image guided biopsy, distinguish early aggressive vs. indolent cancers, and monitor response to therapy. We have assembled a highly interdisciplinary team of scientists with highly synergistic expertise and a long collaboration history. We will utilize significant resources at several small companies we have started and plan to further commercialize our most promising technologies. Project 1 focuses on the development of novel cancer triggered self-assembling and disassembling nanoparticles for positron emission tomography (PET) visualization of lung tumors and their response to chemotherapy. Project 2 focuses on the use of magneto- nanotechnology for blood biomarkers, single cell analysis of circulating tumor cells after enrichment and comprehensive analyses of blood-borne lung cancer markers. Project 3 focuses on the biophysical analysis of extracellular vesicles and their role in prostate cancer oncogenesis. Project 4 focuses on molecular imaging of prostate cancer with targeted nanobubbles for combined photoacoustic/ultrasound imaging and self-assembling nanoparticles for photoacoustic imaging. The Administrative Core will facilitate progress towards our milestones, Core 1 will provide resources for nano characterization and fabrication, and Core 2 will facilitate clinical translation by linking our nanotechnologies to existing patient samples, ad ongoing/new clinical trials. Leveraged access to clinical samples and studies include several large clinical trials for lung cancer (MD Anderson Lung Cancer Early Detection Moonshots Program), prostate cancer (The Prostate Active Surveillance Study (PASS) run by the Canary Foundation), and the Stanford-Google[X]- Duke baseline study to study the transition from health to illness in 10,000 individuals being launched in 2015. With our highly interactive and cohesive program focused on developing and validating nanotechnology for earlier cancer detection and prognostication, improved image guided biopsies, anti- cancer therapy response, we will imagine, invent, innovate, and translate.

描述（由应用程序提供）：这个癌症纳米技术中心卓越的转化诊断（CCNE-TD）将来自斯坦福大学和马萨诸塞州技术研究所的科学家和医生汇集在一起，以应对癌症早期发现的巨大挑战，图像指导性活检，对治疗的反应和对侵略性疾病的早期歧视。这项研究建议集中在我们的愿景中，即与体内分子成像结合使用的体外诊断可以显着影响未来的癌症患者管理。此外，我们认为纳米技术可以通过纳米传感器和通过纳米颗粒进行分子成像的体外诊断，并在体外诊断中显着提高体外诊断。我们将研究的两个主要癌症是肺癌和前列腺癌。对于肺癌，我们将应用我们的技术进行早期检测并监测对治疗的反应。对于前列腺癌，我们将使用我们的技术来改善图像指导的活检，区分早期侵略性与懒惰癌，并监测对治疗的反应。我们组建了一个高度高度协同专业知识和悠久协作历史的科学家跨学科团队。我们将在已经开始的几家小公司中利用大量资源，并计划进一步将我们最有前途的技术商业化。项目1的重点是新型癌症的发展，触发了自组装和拆卸纳米颗粒，用于正电子发射断层扫描（PET）可视化肺肿瘤及其对化疗的反应。项目2的重点是将磁纳米技术用于血液生物标志物，富集后循环肿瘤细胞的单细胞分析以及对血源性肺癌标志物的全面分析。项目3的重点是对细胞外蔬菜的生物物理分析及其在前列腺癌中的作用。肿瘤发生。项目4专注于前列腺癌的分子成像，具有靶向纳米泡，用于合并的光声/超声成像和用于光声成像的自组装纳米颗粒。行政核心将促进我们的里程碑的进步，核心1将为纳米表征和制造提供资源，而核心2将通过将我们的纳米技术与现有患者样本联系起来，AD/新的临床试验来促进临床翻译。杠杆获取获得临床样本和研究包括几项大型肺癌临床试验（MD Anderson肺癌早期发现月球概述计划），前列腺癌（前列腺积极监测研究（PASS）由金丝雀基金会运行）以及斯坦福 - 戈格尔[x] - duke-duke基线研究，从而在10,000次开发中进行了互动，以开发10,000个人，并在10,000次启动中进行了互动，并启动了2015年，该计划是在2015年启动的。并验证纳米技术以进行早期的癌症检测和编程，改进的图像指导活检，抗癌治疗反应，我们会想象，发明，创新和翻译。